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Abstract 
Little is known about factors influencing infant perfluorinated alkyl acid (PFAA) 
concentrations. Associations between serum PFAA concentrations in 2-4-month-old infants 
(n=101) and determinants were investigated by multiple linear regression and General Linear 
Model (GLM) analysis. In exclusively breastfed infants, maternal serum PFAA 
concentrations 3 weeks after delivery explained 13% (perfluoroundecanoic acid, PFUnDA) to 
73% (perfluorohexane sulfonate, PFHxS) of infant PFAA concentration variation. Median 
infant/maternal ratios decreased with increasing PFAA carbon chain length from 2.8 for 
perfluoroheptanoic acid (PFHpA) and perfluorooctanoic acid (PFOA) to 0.53 for PFUnDA, 
and from 1.2 to 0.69 for PFHxS and perfluorooctane sulfonate (PFOS). Infant PFOA, 
perfluorononanoic acid (PFNA) and PFOS increased 0.7-1.2% per day of gestational age. 
Bottle-fed infants had 2 times lower mean concentrations of PFAAs, and a higher mean 
percentage of branched (%br) PFOS isomers, than exclusively breastfed infants. PFOA, 
PFNA and PFHxS increased 8-11% per week of exclusive breastfeeding. Infants living in an 
area receiving PFAA-contaminated drinking water had 3-fold higher mean perfluorobutane 
sulfonate (PFBS) and PFHxS concentrations, and higher mean %br PFHxS. Pre- and post-
natal PFAA exposure significantly contribute to infant PFAA serum concentrations, 
depending on PFAA carbon-chain length. Moderately PFBS- and PFHxS-contaminated 
drinking water is an important indirect exposure source.  
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Introduction 
Per- and polyfluoroalkyl substances (PFASs) are synthetic fluorinated substances used in 
numerous commercial applications and occurring ubiquitously in humans and the 
environment. Sources of human exposure include food, drinking water, dust, air and the use 
of PFAS-containing consumer products.1-4 Among the ~3000 known PFASs,5 perfluoroalkyl 
acids (PFAAs) are of greatest concern due to their persistence and chain length-dependent 
bioaccumulation potential.6 PFAAs may be formed from degradation of other PFASs 
(commonly referred to as PFAA precursors).7,8 
PFAAs could cross the placenta and are excreted in mother´s milk.9-11 Modeling of 
infant exposure to some PFAAs suggests that in utero exposure and breastfeeding are 
important determinants of blood concentrations.12,13 Food, drinking water, dust and air 
contribute to exposure when the child gets older.4,14-17 High early life exposure to some 
PFAAs is related to lower birth weight and immune toxicity, 18-20 and knowledge of 
determinants of PFAS concentrations in infant blood is urgently needed for identification of 
infant exposure sources. Moreover, as pointed out by Loccisano et al.12 more data on PFAA 
concentrations in infants is crucial for development/refinement of infant physiologically-
based pharmacokinetic (PBPK) models, which are important for risk assessment. To our 
knowledge only one study has reported PFAA concentrations in infants (6 months old),21 
showing higher median concentrations of perfluorohexane sulfonate (PFHxS), 
perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and perfluorononanoic acid 
(PFNA) in infant serum than in cord serum from the same study participants. The increase 
was most likely due to exposure during breastfeeding.21 
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The aim of the present study was to investigate maternal to infant transfer of PFHxS 
(linear and branched isomers), PFOS (linear and branched isomers), perfluoroheptanoic acid 
(PFHpA), PFOA, PFNA, perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid 
(PFUnDA), as well as influence of potential determining factors of infant serum 
concentrations, such as maternal PFAA concentrations close to delivery, duration of in utero 
exposure (days of gestational age at delivery), duration of breastfeeding, infant weight gain, 
and maternal exposure to PFAA-contaminated drinking water. 
 
Methods 
Study Population 
The study is based on samples and data collected within the POPUP cohort (Persistent 
Organic Pollutants in Uppsala Primiparas), an on-going investigation of POPs in first-time 
mothers and their children that started in 1996.22 The present study is based on recruitment of 
mother/child pairs 1996-1999. From early fall 1996 to May 1999, 395 randomly selected 
primipara women in late pregnancy were asked to participate in the study.23 The Swedish 
speaking women had been recruited in early pregnancy as controls in a case-control study of 
caffeine as a risk factor for miscarriage.24 In total 325 women (82%) agreed to participate in 
the POPUP study. 
The participating women were asked if a maternal blood sample could be taken 3 weeks 
after delivery and an infant sample about 3 months after delivery. The mothers were Swedish-
born and had singleton births with no birth defects. Almost all women had a full-term 
pregnancy (37–42 weeks), except in a few cases with the shortest gestational age being 35 
weeks and the longest 43 weeks. Women in the POPUP cohort are homogenous regarding 
ethnic background. In 2006, only about 4% of the Swedish population had one or two foreign-
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born parents.25 Maternal sampling 3 weeks after delivery was accepted by 211 participants. 
Infant sampling was accepted by 138 participants. Due to limited blood volumes 101 maternal 
and 107 infant samples were available for PFAA analyses (Table 1). In total 101 matched 
mother/infant samples were available. Informed consent was obtained from all participating 
women. The study was approved by the Ethics Committee of the Medical Faculty at Uppsala 
University (2004:M-177). 
 
Interviews, Questionnaires and Blood sampling 
In-person interviews, using a structured questionnaire, were conducted at 6-12 and 32-34 
completed gestational weeks.24 Height of the women was measured and women were weighed 
on both interview occasions. Data on maternal characteristics included age, pre-pregnancy 
body mass index (BMI), years of education, place of residence, and smoking habits. At the 
infant sampling, the mothers answered a self-administered questionnaire including questions 
about delivery, and personal characteristics not covered by the interviews, such as data on 
breast-feeding. Vacutainer® or Vacuette® serum tubes were used for blood sampling, and after 
separation serum was stored at -20°C until analysis. 
 
Chemical Analyses 
The target analytes included C4, C6 and C8 perfluoroalkane sulfonic acids (PFSAs; PFBS, 
PFHxS, PFOS) and C6-C15 perfluoroalkyl carboxylic acids (PFCAs; PFHxA, PFHpA, PFOA, 
PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFTeDA, PFPeDA; for details see Supporting 
Information, Table A1). The serum samples were analyzed as described previously.26 In short, 
serum (0.1 g for infants and 0.5 g for adults) was spiked with internal standards (Supporting 
Information, Table A2) and extracted with acetonitrile (Honeywell CHROMASOLV™, 
≥99.95% purity) in an ultrasonic bath. The concentrated extract underwent dispersive clean-up 
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with graphitized carbon (Supelclean™ ENVI-Carb™, Sigma-Aldrich). Aqueous ammonium 
acetate (2mM; EMSURE®, Sigma-Aldrich) and volumetric standards (13C8-PFOS and 
13C8-
PFOA; both from Wellington Labs) were added before instrumental analysis on an Acquity 
ultra performance liquid chromatography system (UPLC) coupled to a Xevo TQ-S tandem 
mass spectrometer (both Waters Corp., Milford, MA, U.S.) operated in negative electrospray 
ionization, multiple reaction monitoring mode. The mobile phase consisted of water and 
acetonitrile (ACN; both containing 2mM ammonium acetate), with the relative proportions 
varied under gradient conditions. ACN-based mobile phases such as that used here are highly 
effective at removing bile acid interferences which may affect PFOS and PFHxS analysis.27-29 
Further, instrumental parameters are provided in Supporting Information (Table A2). 
Quantification was performed by isotope dilution using a 5-point external calibration curve 
(linear, 1/x weighting), which was run before and after samples. For most targets, analogous 
isotopically labelled internal standards were available. For PFBS, PFTrDA, PFTeDA, and 
PFPeDA, a structurally similar internal standard was used (Supporting Information, Table 
A2). For PFHxS and PFOS, the linear isomer and the sum of all branched isomers (as one 
signal) were quantified separately using a linear isomer calibration curve. For PFOS, 
concentrations obtained from the m/z 499/80 and 499/99 ions were averaged, which provides 
a reasonable estimate of the weight % branched (%br) content in the absence of isomer-
specific quantification.30 PFHxS was also monitored using m/z 399/80 and 399/99 ions; 
however, since the branched isomer peak in the latter transition was often below method 
detection limits (MDLs), concentrations were only reported from the m/z 399/80 transition.  
Both a procedural blank (0.1 or 0.5 mL Milli-Q water) and QC sample (pooled human 
serum analyzed repeatedly in-house) were included with every batch of samples (see 
Supporting Information, Table A3, for QC performance metrics). In addition, concentrations 
determined in n = 3 replicates of NIST SRM 1957 were compared to reference values to 
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assess the accuracy of the method (results provided in Supporting Information Tables A4 and 
A5). Measured concentrations in SRM 1957 were consistent with reference values for all 
targets, while coefficients of variation (CVs) in in-house reference serum ranged from 12 - 
36% (median 19%; n = 20; Table A3). For targets observable in method blanks, the MDL was 
based on the mean blank + 3× the standard deviation of the blanks. For those targets with no 
observable blank contamination, detection limits were based on the concentration producing a 
signal-to-noise ratio of 3 in sample chromatograms. Analyses of PFAAs in infants and their 
mothers were accomplished within three different analytical batches in 2013, 2014, and 2016. 
Batch-specific MDLs are provided in Table A6 of the Supporting Information. Further 
method validation parameters are provided in Glynn et al. 2012.26 
 
Statistical Analyses 
MINITAB 15® Statistical Software for Windows was used for all statistical analyses. When 
PFAA concentrations were below the method detection limit (MDL), MDL/√2 was taken as 
an estimated value in the statistical analyses. The PFAA concentrations in maternal serum 
were measured in different analytical batches and for PFHpA and PFBS the MDL differed 
between the batches (Supporting Information Table A6). In the statistical analysis including 
maternal PFAA data, all PFHpA and PFBS data below MDL in the batch with the highest 
MDL was omitted (batch 3, n=17). The proportions of branched and linear isomers for PFHxS 
and PFOS were expressed as a percentage of the total concentration. Correlations between 
infant and mother serum PFAA concentrations were investigated using the Pearson´s 
correlation test, and only pairs with data >MDL for both the mother and the infant were 
included in the analyses.  
For PFAAs with over 75% of infant data >MDL multiple linear regressions were used 
to analyze if infant serum concentrations are influenced by maternal PFAA concentrations 3 
9 
 
weeks after delivery (ng g-1), gestational age at delivery (days), infant weight gain (% of birth 
weight) and duration of breastfeeding (weeks) (Table 1). The inclusion of the potential 
determinants were based on the assumption that they may influence fetal/infant exposure 
(maternal PFAA concentrations, gestational age, duration of breastfeeding) or infant PFAA 
distribution volume (infant weight gain). In univariate analyses infant PFAA concentrations 
did not differ between sexes (Mann-Whitney U test, p>0.05), and infant sex was not included 
as a covariate in the regression models. In this analysis, only data from infants that were 
exclusively breastfed during the whole study period from birth to infant blood sampling were 
included. Stepwise regression analysis was used to estimate how much of the variation in 
PFAA concentrations that could be explained by the variation of each individual determinant 
(partial coefficient of determination, R2). Criteria for determinant inclusion in the regression 
model was α<0.15, but in the analyses determinants with α≥0.15 were forced to be included in 
order to assure that the same model was used in all analyses. Partial R2 for each significant 
determinant (p≤0.05) was calculated by subtraction of the R2 of the model not including the 
determinant in question from the R2 of the model including the determinant in question. 
In separate general linear model (GLM) analyses, using all participating mother/infant 
pairs, the influence of breastfeeding on infant PFAA concentration was investigated. Maternal 
PFAA concentration was used as a covariate in the GLM model, and infants were divided into 
a group that were exclusively bottle-fed from birth to sampling, a group with mixed breast-
/bottle-feeding, and infants that were exclusively breastfed. 
As only three of the formula-fed infants were living in a city district that received 
contaminated drinking water, it was not possible to statistically analyze the influence of direct 
drinking water exposure from formula feeding. Instead, the influence of maternal drinking 
water PFAA exposure on infant PFAA concentrations was investigated by grouping 
participants according to home address in city districts receiving drinking water with different 
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contributions from PFAA-contaminated production well water. Uppsala County and the City 
of Uppsala can be divided into different drinking water districts depending on proportion of 
contaminated drinking water distributed to the districts.31 There were two districts that did not 
receive any water from the contaminated wells from 1996 to 1999, comprised of  i) areas 
outside the City of Uppsala and ii) District 1 within the city. District 2 in the City of Uppsala 
received drinking water containing <10% water from contaminated wells, District 3 received 
10-90% contaminated water, and District 4 received >90% water from contaminated wells.31 
GLM analysis was used to calculate adjusted means of PFAA concentrations for the different 
city districts, with “days of gestational age”, “infant weight gain after birth” and “duration of 
breastfeeding” included as covariates in the GLM model. Maternal PFAA concentration was 
not included as covariate since this would result in over-adjustment of the association between 
infant city district and infant PFAA concentrations. Maternal PFAA concentrations are on the 
casual pathway between city district and infant PFAA. Exclusively bottle-fed infants were not 
included in the analyses (N=5). 
Logarithmically-transformed infant PFAA concentrations were used in the regression 
and GLM analyses, since the distribution of data closely followed a log-normal distribution. 
Observations with standardized residuals ≥3 were excluded from regression and GLM 
analysis due to their large influence on the results. The statistical significance level was set to 
p≤0.05. 
 
Results and Discussion 
Serum Concentrations in Infants and Their Mothers 
PFOS showed the highest median concentration followed by PFOA, PFHxS, PFNA, PFDA 
and PFUnDA in both infants and mothers (Table 2). Concentrations of short-chain PFBS, 
PFHxA and PFHpA were in many cases <MDL. Among the long-chain PFCAs (>7 
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fluorinated carbon atoms) median concentrations decreased with increasing chain length in 
both infants and mothers, with >50% of concentrations below MDL for PFDoDA, PFTrDA, 
PFTeDA and PFPeDA (Table 2). The observed concentrations differ from those reported for 
6-month-old infants from Germany,21 the only previously published infant study we could 
find in the literature. Different sampling periods (present study:1996-99, German study:2007-
2009) and ages of the infants (present study:2-4 months, German study: 6 months) are most 
likely important determinants of the observed differences. 
To our knowledge, no other study has reported isomer-specific data on PFHxS and 
PFOS for infants. We found similar %br PFOS and PFHxS in mothers and infants (Table 2), 
suggesting that infant isomer patterns to a large extent are dependent on maternal patterns. In 
Canadian mothers, median %br PFOS (36%) was similar to that of Swedish mothers, 
although Canadian mothers were sampled almost 10 years after the Swedish mothers.32 In 
maternal serum from China, sampled 2015-2016, branched PFHxS accounted for 14% 
(median) of the total PFHxS and branched PFOS 17% of total PFOS.33 A comparison of 
maternal %br PFHxS and PFOS between studies is hampered by differences in how branched 
content was determined in each study (e.g. isomer-specific versus sum branched isomer 
quantification using linear and/or individual branched isomer standards). Nevertheless, 
differences due to ongoing maternal exposure to for instance PFHxS and PFOS precursors in 
China are likely since perfluorooctane sulfonyl fluoride-based chemistry is still used in 
China.33 
Maternal serum/plasma concentrations of PFHxS, PFOS, PFOA, PFNA, PFDA, and 
PFUnDA during pregnancy and a few weeks after delivery both reflect placental and mother´s 
milk PFAA transfer, as shown by strong correlations between PFAA concentrations in 
maternal and cord blood, and between concentrations in maternal blood and mother´s 
milk.9,10,26,34,35 We found positive correlations between maternal and infant PFAA 
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concentrations, with weakening strength as chain length increased of both long-chain PFCAs 
and PFSAs (Table 3). This suggests that factors other than maternal concentrations become 
more important as determinants for infant PFAA concentrations as perfluoroalkyl chain length 
increases.  
This is further supported by the decreased strength of association between maternal and 
infant concentrations with increased PFAA carbon chain length among exclusively breastfed 
infants, as determined in multiple log-linear regression analyses (Table 4). Variation in 
maternal PFOA concentrations explained 53% of the infant concentration variation, whereas 
only 13% of the variation in infant PFUnDA was explained by maternal variation. For 
PFHxS, 73% of the infant variation was explained by maternal variation, and the 
corresponding figure for PFOS was 36%. The short-chain PFHpA deviated from this pattern 
of chain-length dependency, showing a weaker infant/mother correlation than PFOA did 
(Table 3) and a weaker strength of association (Table 4). For PFAA homologues with less 
strong infant/mother correlations and associations, contribution of infant exposure sources not 
studied by us may be important, including ingestion of dust, suction on materials containing 
PFASs, inhalation of fine particles/air, and skin exposure through use of personal care 
products.4 To what degree these different exposure pathways contribute to total infant 
exposure has not been fully characterized, but the contribution of each component most 
probably varies with infant age.4 
Our results suggest that PFAA transfer efficiency from mother to infant decreases with 
increasing perfluoroalkyl chain length, as indicated by the infant/maternal serum 
concentration ratios (Table 3). On average, PFHpA and PFOA showed higher concentrations 
in infants than in mothers, PFHxS concentrations were similar, and concentrations for PFNA, 
PFOS, PFDA and PFUnDA were lower in infants. This is in agreement with the previously 
observed chain length-dependent decrease in transfer efficiency over the placenta and from 
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maternal blood to mother´s milk.9,32,36,37 It has been proposed that decreases in PFAA 
placental transfer with increased chain length may be due to decreases in water solubility and 
increases in PFAA affinity to serum albumin.4,37 It has also been hypothesized that there are 
chain length differences in active PFAA transport in the placenta,4,11 although this hypothesis 
has to our knowledge not been tested. Similarly, it is not known to what degree mammary 
gland active PFAA transport is involved in the carbon chain-dependency of PFAA transfer to 
mother´s milk. 
In contrast to Fromme et al.21, our study does not include matched cord blood data. We 
have previously published cord whole blood data for PFOS, PFOA and PFNA in the Uppsala 
study 1996-99.26 Assuming a distribution factor of 2 between serum and whole blood, average 
cord serum concentrations were 2-3 times lower than those in maternal serum sampled in late 
pregnancy,26 which is in accordance with data from Fromme et al.21 A comparison of 
published cord/maternal serum or plasma PFAA ratios with the infant/maternal serum PFAA 
ratios among Uppsala infants (Table 3) and German infants (plasma) show that the 
infant/maternal ratios generally are higher than the cord/maternal rations.21,32,36 This strongly 
suggests that breastfeeding gives a significant contribution to the PFAA exposure of the 
infants.  
The similar median ratios of infant/maternal linear and branched PFHxS, as well as of 
PFOS isomers (Table 3), show that linear and branched isomers were retained in the infants to 
a similar degree as in their mothers. A few studies have reported less efficient placental 
transfer of linear PFOS (relative to branched), but found no isomer specific differences in 
transfer via mother´s milk.10,32,35 To our knowledge, only one study has reported placental 
transfer efficiencies of PFHxS isomers showing, contrary to PFOS, a more efficient transfer 
of the linear isomer than of the branched isomers.33 Our results suggest that the more efficient 
trans-placental transfer of branched PFOS, and less efficient transfer of branched PFHxS, are 
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“compensated for” after birth, presumably from mother´s milk, resulting in similar %br 
isomers in mothers and infants. 
 
Impact of Duration of Breastfeeding, Gestational Age and Infant Weight Gain 
Concentrations of PFOA, PFNA, PFDA, PFUnDA, PFHxS and PFOS were lower in 
exclusively bottle-fed infants than in exclusively breastfed infants, strongly suggesting that 
mother´s milk is an important source of infant exposure to all these PFAAs (Fig. 1). The 
results are however uncertain since we only had 5 exclusively bottle-fed infants, but the 
importance of breastfeeding as an exposure source of all these PFAAs is supported by our 
findings of lower serum PFAA concentrations also among mixed breast-/bottle-fed infants 
(Fig. 1). The lower PFAA concentrations in bottle-fed infants are most probably a net result of 
infant excretion and growth dilution of PFAAs accumulated in utero, and much lower PFAA 
exposures from infant formula than from mother´s milk.38,39 No exclusively bottle-fed infants 
were living in a district receiving contaminated drinking water, so it was not possible to 
determine the contribution of this potential exposure route.  
The higher %br PFOS in the few exclusively bottle-fed infants than in exclusively 
breastfed infants (Fig. 1) is most probably a result of the higher placental transfer of branched 
PFOS isomers than of the linear isomer, and a “mother´s milk compensation” with the linear 
isomer among exclusively breastfed infants.10,32,35 Branched PFOS isomers are preferentially 
excreted in urine in adults compared with the linear isomer,40,41 but excretion of different 
PFOS isomers in infants apparently was too slow to cause preferential retention of the linear 
isomer in bottle-fed infants. The reported lower trans-placental transfer efficiency of branched 
PFHxS isomers than of the linear isomer33 did not result in lower %br PFHxS concentration 
in the exclusively bottle-fed infants (Fig. 1). Assuming that the excretion of PFHxS was 
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negligible during infancy, the results suggests that the transfer of branched PFHxS isomers to 
mother´s milk is not higher than transfer of the linear isomer. 
In the multiple regression analyses of PFAA concentrations in exclusively breastfed 
infants, duration of breastfeeding explained <10% of the variation in infant PFAA 
concentrations, with estimated increases in serum concentrations of ≤10% per week of 
breastfeeding as the infant age at sampling increased from 11 to 18 weeks (Table 4). 
Associations with breastfeeding were statistically significant for PFOA, PFNA and PFHxS. 
The low variation in duration of breastfeeding (7 weeks) among the exclusively breastfed 
infants may have contributed to the relatively weak associations. Only exclusively breastfed 
infants were included in the analyses, and duration of breastfeeding was therefore the same as 
infant age. Physiological changes during infancy may influence associations between PFAAs 
and breastfeeding duration, including for instance possible age-dependent differences in 
efficiency of infant intestinal PFAA absorption and excretion, as well as in body PFAA 
distribution. 
In our study, PFOA concentrations increased on average 8% per week of exclusive 
breastfeeding, corresponding to about 30% per month. The increase for PFNA was estimated 
to on average 45% per month and for PFHxS 40% per month. Similar results were observed 
for 1.5-year-old children from the Faroe Islands, with PFOA increasing 30% per month of 
exclusive breastfeeding and PFNA 20% per month.42 Among 3-4 year-old children from 
Norway and USA, every month of breastfeeding was associated with a 3-6% increase in 
PFHxS, PFOS and PFOA in child serum.16,17 The lower contribution of breastfeeding in the 
older children is most probably  an effect of excretion of maternally transferred PFAA and 
contribution of non-maternal sources of PFAA exposure during childhood. 
Our results suggests that duration of in utero exposure influences infant concentrations 
of PFOA, PFNA and PFOS up to 2-4 months after delivery, since days of gestational age in 
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general was positively associated with infant PFAA concentrations (Table 4). However, the 
associations were fairly weak, explaining only 2-10% of the variation in infant concentrations 
of PFOA, PFNA and PFOS. An earlier study found strong positive correlations between fetal 
age and fraction of maternal PFAAs present in fetal tissue.43 Residual confounding of the 
gestational age-PFAA associations cannot be excluded. For instance a study from Canada 
reported that increases in maternal gestational weight gain (GWG), which increases with 
gestational age, were associated with elevated cord blood PFOS and PFOA concentrations44 
Inclusion of maternal weight gain as a covariate in the regression models did however not 
change the associations between gestational age and PFOA, PFNA and PFOS serum 
concentrations in exclusively nursed infants (Supporting Information, Table A8). Birth 
weight, which is associated with gestational age, may be another potential confounder through 
influence on distribution volume of infant PFAAs. For PFNA and PFOS inclusion of birth 
weight as a covariate did not influence the associations with gestational age, but for PFOA the 
association became weaker (Supporting Information, Table A8). 
Branched PFOS isomers increased on average with 1% per day of gestational age, 
whereas the linear isomer increased 0.75% per day of gestational age (Table 4), supporting a 
higher placental transfer of branched as opposed to linear isomers.32,33 No significant change 
in branched and linear PFHxS per day of gestational age was observed, further supporting the 
low influence of gestational age on serum PFHxS concentrations in infants at 2-4 months of 
age (Table 4). 
It may be hypothesized that infant weight gain affects PFAA concentrations due to 
growth dilution of PFAA accumulated pre- and post-natally. However, the inverse association 
was only significant (p=0.03) for PFHpA (Table 4), explaining about 10% of variation in 
infant concentrations (Table 4). Infant PFHpA concentrations decreased on average about 1% 
with each percentage of weight gain during the study period (Table 4). The infant weight gain 
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effect on concentrations of other PFAAs than PFHpA was not large enough to be detected in 
the multiple regression analyses.  
 
Impact of Contaminated Drinking Water. 
In 2012, a PFAA contamination was discovered in Uppsala drinking water, with distribution 
of contaminated drinking water to some city districts dating back to at least 1996-1999.31 The 
affected production wells were quickly taken out of production after the discovery of the 
contamination. In 2012-2014, the median PFHxS concentration was 80 ng L-1 in contaminated 
drinking water production wells, followed by PFOS (50 ng L-1), and PFBS and PFHxA (both 
10 ng L-1). Our results suggest that maternal ingestion of the moderately PFHxS- and PFBS-
contaminated drinking water strongly influence serum concentrations of the two PFAAs in 
infants (Fig 2). The adjusted mean infant serum concentrations of PFBS and PFHxS were 
about 3-fold higher among infants living in District 4, receiving >90% PFAA-contaminated 
drinking water between 1996 and 1999, than among infants living in the districts not receiving 
contaminated water (Fig. 2). 
Similarly as among Uppsala mothers,31 no influence of contaminated drinking water on 
infant PFOS concentrations was observed (Supporting Information, Table A7), although 
PFOS concentrations in the contaminated drinking water were only slightly lower than those 
of PFHxS and much higher than PFBS concentrations. Taken together the results suggest that, 
in contrast to PFBS and PFHxS, maternal PFOS exposure sources other than drinking water 
were more important indirect determinants of infant PFAA concentrations. 
%br PFHxS was significantly higher in infants living in Uppsala districts receiving 10-
90% and >90% contaminated water than in infants living in the district receiving 
uncontaminated water (Fig. 2). We have previously proposed that increased %br PFHxS in 
adult serum, compared to background in a population, may be an indicator for drinking water 
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exposure to PFHxS originating from fire-fighting foams.31 Our infant results suggest that 
enrichment of branched PFHxS persists also in infants of mothers exposed to drinking water 
PFHxS. 
 
Strengths and Limitations 
Our study includes data on PFBS, PFHxA, PFHpA, PFUnDA, PFDoDA, PFTrDA, PFTeDA 
and PFPeDA which were lacking in Fromme et al. (2011).21 For many of these PFAA, 
however, concentrations were generally below LOQ, making it impossible to analyze 
associations with potential determinants. We have data on branched and linear isomers of 
PFHxS and PFOS in infants, thus enabling a first look at possible isomer-specific differences 
in mother/infant dynamics of PFHxS and PFOS. We only had PFAA concentration data from 
5 infants that were exclusively bottle-fed, making the comparisons with PFAA concentrations 
in exclusively breastfed infants uncertain. However, with supporting data from partially 
bottle-fed infants we can nevertheless conclude that breast-feeding is a significant source of 
infant exposure to PFHxS, PFOS, PFOA, PFNA, PFDA and PFUnDA. Moreover our study 
includes data on several potential determinants not studied before, such as gestational age 
(duration of in utero exposure), infant body weight gain (growth dilution), and home address 
in drinking water districts with differences in drinking water PFAA contamination (indirect 
drinking water exposure). A weakness is that we did not have data on PFAA concentrations in 
drinking water ingested by the mothers and maternal drinking water consumption, which 
would have improved the analyses of contribution of maternal PFAA drinking water exposure 
to infant serum PFAA concentrations.  
The Swedish infants were only sampled once after birth and more extensive serial 
sampling of neonates and infants will give better information about factors influencing 
serum/plasma PFAA concentrations during early childhood. As shown by the decrease in 
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strength of determination with increasing PFAA chain length, there are unknown 
determinants, not studied by us, that have an important influence on infant PFAA 
concentration.  
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Figure 1. Concentrations (ng g-1 serum) of selected PFAAs in serum from 2-4-month-old infants 
sampled 1996-1999 with different degrees of breastfeeding during the study period. ‘Bottle-fed’ (N=5) 
represents infants which were not breastfed at all prior to sampling. ‘Bottle-/breastfed’ (N=11) 
corresponds to infants that were exclusively breastfed followed by partial/exclusive bottle-feeding 
before sampling. ‘Breastfed’ (N=83) represents infants exclusively breastfed from birth until 
sampling. PFAA concentrations <MDL were replaced with MDL/√2. Concentrations are shown as 
adjusted mean and SE determined by general linear model (GLM) analysis. In the GLM analyses the 
covariate “maternal PFAA serum concentration” was included. Asterisk (*) represents a significant 
difference (p<0.05) relative to infants with exclusive bottle-feeding determined in multiple regression 
analysis.  
21 
 
 
 
0.00
0.01
0.02
0.03
0.04 *
0% <10% 10-89% >90%Outside
of Uppsala
Uppsala districts receiving different amount of
contaminated drinking water
PFBS
n
g
/g
 s
e
ru
m
0
2
4
6
8
*
0% <10% 10-89% >90%Outside
of Uppsala
Uppsala districts receiving different amount of
contaminated drinking water
PFHxS
n
g
/g
 s
e
ru
m
0
5
10
15
*
*
0% <10% 10-89% >90%Outside
of Uppsala
Uppsala districts receiving different amount of
contaminated drinking water
%br PFHxS
%
b
ra
n
c
h
e
d
 i
s
o
m
e
rs
 
Figure 2. Concentrations (ng g-1 serum) of PFBS (N=88) and PFHxS (N=91), as well as %branched 
PFHxS (N=91) in serum from breastfed 2-4-month-old infants sampled 1996-1999, living in different 
drinking water districts in Uppsala County receiving different percentages of drinking water from 
PFAA-contaminated wells. The district “Outside Uppsala” did not receive contaminated water. PFBS 
concentrations <MDL were replaced with MDL/√2. Concentrations are shown as adjusted mean and 
SE determined by general linear model (GLM) analysis. In the GLM analyses the covariates 
“gestational age”, “infant weight gain after birth” and “duration of breastfeeding” were included. 
*Significantly different from district “Outside of Uppsala” in multiple linear regression analyses 
(p<0.05). PFBS: District “Outside Uppsala” N=30, 0% N=40, <10% N=2, 10-90% N=7, >90% N=9. 
PFHxS: District “Outside Uppsala” N=31, 0% N=41, <10% N=2, 10-90% N=7, >90% N=10. 
 
 
  
22 
 
 
Table 1. Characteristics of the mothers and infants investigated in the present study 
Characteristics na Mean Range %b 
Mothers     
Age (year) 101 29 22-41  
Pre-pregnancy BMIc 101 24 18-36  
Years of education 98   100 
   ≤4 years of high school 41   42 
   1-3 years of higher education 27   28 
   >3 years of higher education 30   31 
Infants     
Age at sampling (weeks) 105 13 11-18  
Gestational age (days) 100 280 250-300  
Weight (kg) 103 6.1 4.4-8.6  
Weight gain (% of birth weight) 103 75 30-150  
Exclusive breastfeeding (weeks) 105 12 0-18  
Sampling year 107   100 
1996-1997 48   44 
1998-1999 59   66 
Sex 107   100 
Girls 58   54 
Boys 49   46 
PFAA drinking water districts 107 
   Outside of Uppsala city 38   36 
   Uppsala 1, no PFAA contamination 47   44 
   Uppsala 2, <10% contaminated water 2   2.0 
   Uppsala 3, 10-89% 9   8.0 
   Uppsala 4, ≥ 90% 11   10 
aOf the original 101 mothers 3 mothers had missing data for education. The different total N values for infants 
variables are also due to missing data. bPercent of total N. cBody mass index (kg/m2). 
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Table 2. PFAA serum concentrations in infants at 2-4 months of age and their mothers sampled 3 weeks after delivery 
 Infants  
 
Mothers 
PFAA (ng g-1) Meana SD Median  Range DFb (%) 
 
Meana SD Median  Range DFb (%) 
PFHxA   <0.10 <0.10-0.27 37    <0.08 <0.08-0.11 1 
PFHpA 0.23 0.22 0.19 <0.10-2.1 88    0.055 <0.04-0.40 66c 
PFOA 7.7 3.7 7.2 1.3-20 100  2.8 0.96 2.7 1.2-6.7 100 
PFNA 0.38 0.21 0.34 0.10-1.5 100  0.41 0.20 0.37 0.08-1.4 100 
PFDA 0.12 0.07 0.11 <0.07-0.47 86  0.19 0.11 0.17 <0.05-0.72 94 
PFUnDA 0.09 0.05 0.08 <0.05-0.23 79  0.12 0.09 0.11 <0.05-0.37 64 
PFDoDA   <0.05 <0.05-0.06 3    <0.05 <0.05-0.22 13 
PFTrDA   <0.05 <0.05-0.15 37    <0.05 <0.05-0.19 11 
PFTeDA   <0.05 <0.05-0.13 14    <0.07 <0.07-0.38 4 
PFPeDA     0      0 
PFBS   <0.01 <0.01-0.14 30    <0.01 <0.01-0.15 57c 
Linear PFHxS 2.6 2.2 1.9 0.41-19 100  2.2 1.4 1.7 0.36-8.9 100 
Branched PFHxS 0.21 0.24 0.13 <0.01-1.8 99  0.14 0.13 0.10 <0.01-0.76 96 
%branched PFHxS 6.9 3.0 6.4 1.8-18   5.7 2.9 5.3 0.41-14  
Total PFHxS 2.8 2.5 2.0 0.43-21 100  2.3 1.5 1.8  0.37-9.5 100 
Linear PFOS 8.6 4.0 8.4 1.3-26 100  14 5.6 12 5.0-41 100 
Branched PFOS 5.0 2.9 4.4 0.87-21 100  7.0 3.5 5.8 2.6-20 100 
%branched PFOS 36 6.2 36 26-62   33 4.1 34 24-45  
Total PFOS 14 6.7 13 2.2-44 100  20 8.9 18 7.7-61 100 
aConcentration below MDL were set to MDL/√2 in calculations of mean and SD. Infants: N=107; Mothers: N=101. bDetection frequency. cN=84. MDL differed between the 
3 analytical batches. Those with concentrations below MDL in the batch with the highest MDL deleted from the analyses. 
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Table 3. Relationship between PFAA concentrations in matched infant serum (IS) and 
maternal serum (MS)a 
PFAA N No. of carbons in Ratio IS:MS Spearman´s correlationb 
 
 fluorinated chain 
Median (range) r  p 
PFCAs      
PFHpA 51 6 2.8 (0.56-8.2) 0.31 0.005 
PFOA 101 7 2.8 (0.43-5.7) 0.59 <0.001 
PFNA 101 8 0.94 (0.28-6.4) 0.42 <0.001 
PFDA 54 9 0.69 (0.095-4.0) 0.34 0.001 
PFUnDA 49 10 0.53 (0.21-1.5) 0.18 0.069 
PFSAs      
Linear PFHxS 101 6 1.2 (0.22-2.2) 0.84 <0.001 
Branched PFHxS 101 6 1.3 (0.22-17) 0.80 <0.001 
Total PFHxS 101 6 1.2 (0.22-2.3) 0.85 <0.001 
Linear PFOS 100 8 0.66 (0.095-1.4) 0.37 <0.001 
Branched PFOS 100 8 0.72 (0.19-1.7) 0.46 <0.001 
Total PFOS 100 8 0.69 (0.14-1.5) 0.39 <0.001 
aOnly infant/mother pairs with concentrations ≥MDL included in the analyses. Infants sampled 2-4 months after delivery, 
mothers 3 weeks after delivery. bCorrelation between infant and maternal PFAA concentrations. 
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Table 4. Percent change in serum PFAA concentrations in exclusively breastfed infants per unit change of maternal PFAAs, gestational 
age, and infant weight gaina 
PFAA No. of Maternal PFAA (ng g-1) Gestational age (days) Breastfeeding (weeks) Weight gain (% of birth weight)  
 carbons β 
(% change) 
P (partial R2) β 
(% change) 
P (partial R2) β 
(% change) 
P (partial R2) β 
(% change) 
P (partial R2) Full R2 
% 
PFHpA (N=62)b 6 380 (123) 0.003 (4%) 1.1 (0.78) 0.178 7.5 (7.5) 0.32 -0.87 (0.38) 0.03 (12%) 27 
PFOA (N=70) 7 26 (2.6) <0.001 (53%) 0.67 (0.29) 0.028 (2%) 8.0 (2.8) 0.006 (6%) 0.010 (0.014) 0.92 63 
PFNA (N=75) 8 150 (20) <0.001 (33%) 1.2 (0.42) 0.004 (10%) 11 (4.1) 0.007 (6%) 0.0070 (0.18) 0.97 48 
PFDA (N=75) 9 200 (40) <0.001 (23%) 0.91 (0.47) 0.058 8.3 (4.5) 0.068 -0.21 (0.20) 0.31 33 
PFUnDA (N=75) 10 220 (66) 0.001 (13%) 0.02 (0.6) 0.980 5.6 (5.9) 0.34 0.21 (0.27) 0.45 14 
Linear PFHxS (N=75) 6 35 (2.4) <0.001 (72%) 0.45 (0.41) 0.271 10 (3.8) 0.01 (2%) -0.09 (0.18) 0.63 76 
Branched PFHxS (N=75) 6 600 (47) <0.001 (67%) -0.07 (0.63) 0.913 9.6 (5.9) 0.11 0.10 (0.28) 0.71 71 
PFHxS (N=75) 6 32 (2.2) <0.001 (73%) 0.44 (0.41) 0.294 10 (3.9) 0.01 (2%) -0.080 (0.2) 0.64 76 
Linear PFOS (N=73) 8 4.2 (0.56) <0.001 (36%) 0.75 (0.34) 0.031 (3%) 2.9 (3.1) 0.29 0.25 (0.15) 0.10 50 
Branched PFOS (N=74) 8 8.2 (1.2) <0.001 (37%) 1.0 (0.47) 0.036 (4%) 2.9 (4.4) 0.51 0.29 (0.21) 0.16 45 
PFOS (N=73) 8 2.9 (0.38) <0.001 (36%) 0.84 (0.36) 0.025 (4%) 3.1 (3.4) 0.36 0.22 (0.16) 0.19 46 
aAdjusted mean (standard error). Mutually adjusted for each other in the multiple regression model. Outliers with standardized residual ≥3 excluded in the regression analyses. Partial R2 was 
estimated by stepwise regression analyses. bMDL differed between analytical batches. Mother/infant pairs with concentrations below MDL in the batch with the the highest MDL deleted from 
the analyses.  
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Supporting Information 
PFAAs included in the study (Table A1). Target compounds and selected instrumental 
parameters for quantification of each compound by UPLC/ESI-MS/MS (Table A2). Summary 
of analysis of in-house reference material (pooled human serum) analyzed together with real 
samples to assess inter-batch precision (i.e. reproducibility) (Table A3). PFCA concentrations 
measured in 3 replicates of NIST SRM 1957 compared to reference values (Table A4). PFSA 
concentrations measured in 3 replicates of NIST SRM 1957 compared to reference values 
(Table A5). Method detection limits for PFASs analyzed in each of the three batches (Table 
A6). Concentrations of PFAAs in serum from 2-4-month-old children sampled 1996-1999, 
living in different drinking water districts in the Uppsala County (Table A7). The influence of 
maternal weight gain during pregnancy and birth weight on percent change in serum PFAA 
concentrations per unit change of gestational age in exclusively breastfed infants (Table A8). 
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 Table A1. PFAAs included in this study. 
Substance 
No. of carbons in 
fluorinated chain 
Abbreviation 
Perfluoroalkyl carboxylic acids (PFCAs)  
Perfluorohexanoic acid 5 PFHxA 
Perfluoroheptanoic acid 6 PFHpA 
Perfluorooctanoic acid 7 PFOA 
Perfluorononanoic acid 8 PFNA 
Perfluorodecanoic acid 9 PFDA 
Perfluoroundecanoic acid 10 PFUnDA 
Perfluorododecanoic acid 11 PFDoDA 
Perfluorotridecanoic acid 12 PFTrDA 
Perfluorotetradecanoic acid 13 PFTeDA 
Perfluoropentadecanoic acid 14 PFPeDA 
Perfluoroalkyl sulfonic acids (PFSAs)   
Perfluorobutane sulfonic acid 4 PFBS 
Perfluorohexane sulfonic acida 6 PFHxS 
Perfluorooctane sulfonic acida 8 PFOS 
aBranched and linear isomers 
  
 Table A2. Target compounds and selected instrumental parameters for quantification of each 
compound by UPLC/ESI-MS/MS. 
Target Analytesa, c Precursor / product ion 
(qualitative product ion)b 
Cone 
voltage (V) 
Collision 
energy (eV) 
Internal 
standardsc 
PFBS 299 / 80 (99) 45 30 13C2-PFHxS 
PFHxS 399 / 80 (99) 55 36 18O2-PFHxS 
PFOS 499 / 80 (99) 65 40 13C4-PFOS 
PFHxA 313 / 269 (119) 20 10 13C2-PFHxA 
PFHpA 363 / 319 (169) 21 11 13C4-PFHpA 
PFOA 413 / 369 (169) 22 11 13C4-PFOA 
PFNA 463 / 419 (219) 24 11 13C5-PFNA 
PFDA 513 / 469 (269) 26 11 13C2-PFDA 
PFUnDA 563 / 519 (269) 28 11 13C2-PFUnDA 
PFDoDA 613 / 569 (169) 30 12 13C2-PFDoDA 
PFTrDA 663 / 619 (169) 32 12 13C2-PFDoDA 
PFTeDA 713 / 669 (169) 35 12 13C2-PFDoDA 
PFPeDA 763 / 719 (169) 38 13 13C2-PFDoDA 
     
Recovery Standards     
13C8-PFOA 421 / 376 22 11  
13C8-PFOS 507 / 80 65 42  
aAcronyms are according to (Buck et al., 2011).1 
bProduct ions in brackets were used as confirmation ions. 
cAll standards were purchased from Wellington Laboratories (Guelph, ON, Canada). 
 
 
 Table A3. Summary of PFAS concentrations (ng/mL) in-house reference material (pooled human serum) analyzed together with real samples to 
assess inter-batch precision (i.e. reproducibility). Two different QC samples were included: Control A (n = 17) and Control B (n = 3). Non-detects 
(ND) were not included in determination of averages or coefficient of variations (CVs). 
Reference 
Material 
PFHxA PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA PFTeDA PFPeDA PFBS 
∑br-
PFHxS 
lin-
PFHxS 
∑br-PFOS 
(Avg. 80+99) 
lin-PFOS-
80 
A-1 ND ND 1.09 0.54 0.19 0.31 ND 0.12 ND ND ND 0.03 0.73 0.95 2.36 
A-2 ND ND 1.30 0.65 0.25 0.29 ND 0.08 ND ND ND 0.06 0.68 0.95 2.42 
A-3 ND ND 1.60 0.47 0.25 0.30 ND 0.12 ND ND ND 0.05 0.71 0.98 2.39 
A-4 ND ND 1.53 0.59 0.25 0.27 ND 0.11 ND ND ND 0.05 0.75 1.10 2.55 
A-5 ND ND 1.45 0.65 0.33 0.41 0.05 0.08 ND ND 0.07 0.03 0.83 2.07 2.87 
A-6 ND ND 1.18 0.61 0.31 0.30 ND 0.09 ND ND ND 0.02 0.88 1.53 2.11 
A-7 ND ND 1.47 0.68 0.27 0.50 0.06 0.14 ND ND 0.04 0.04 0.77 1.84 2.25 
A-8 ND ND 1.80 0.59 0.30 0.44 0.08 0.10 ND ND 0.06 0.04 0.85 2.12 3.02 
A-9 ND ND 1.52 0.69 0.47 0.35 0.09 0.08 ND ND ND 0.06 0.91 3.13 3.64 
A-10 ND ND 1.69 0.82 0.31 0.42 0.04 0.05 ND ND 0.05 0.04 0.96 2.41 2.72 
A-11 ND ND 1.48 0.70 0.31 0.42 ND 0.08 ND ND ND 0.04 0.79 2.53 3.46 
A-12 ND ND 1.31 0.64 0.25 0.36 0.05 ND ND ND ND 0.04 0.78 2.18 2.75 
A-13 ND ND 1.41 0.59 0.28 0.35 0.05 0.04 ND ND ND 0.02 0.91 2.24 3.58 
A-14 ND ND 1.36 0.66 0.24 0.35 0.05 0.05 ND ND 0.06 0.02 0.91 1.62 2.83 
A-15 ND ND 1.34 0.71 0.29 0.34 ND ND ND ND ND 0.02 0.61 1.91 3.05 
A-16 ND ND 1.22 0.67 0.22 0.36 ND 0.06 ND ND ND 0.03 0.90 1.79 1.93 
A-17 ND ND 1.35 0.54 0.23 0.44 0.06 0.04 ND ND ND 0.05 0.70 1.58 2.33 
Avg Ref 
Material A ND ND 1.42 0.64 0.28 0.36 0.06 0.08 ND ND 0.06 0.04 0.80 1.82 2.72 
CV Ref 
Material A ND ND 12.9 12.6 22.8 17.6 30.1 36.4 ND ND 18.9 34.9 12.4 33.6 18.6 
B-1 ND ND 2.99 0.23 0.14 0.15 ND ND ND ND 0.01 0.12 2.23 3.67 8.59 
B-2 ND ND 2.03 0.48 0.21 0.23 ND ND ND ND 0.02 0.13 2.03 3.31 8.94 
B-3 ND ND 2.45 0.32 0.30 0.17 ND ND ND ND ND 0.18 2.31 2.87 6.34 
Avg Ref 
Material B ND ND 2.49 0.34 0.22 0.18 ND ND ND ND 0.01 0.15 2.19 3.28 7.96 
CV Ref 
Material B ND ND 19 37 38 21 ND ND ND ND 34 23 7 12 18 
Pooled CV 
(A+B material) ND ND 13 17 24 18 30 36 ND ND 23 33 12 32 18 
 
 Table A4. PFCA concentrations (mean ± 95% confidence intervals) measured in n = 3 replicates of NIST SRM 1957 compared to reference 
values. ND = non-detect. NA = not available.  
PFHxA PFHpA PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA PFTeDA PFPeDA 
Mean (this 
study; ng g-1) 
<0.160 0.278 ± 0.091 4.04 ± 1.77 0.818 ± 0.135 0.24 ± 0.13 0.121 ± 0.052 <0.030 <0.020 <0.060 <0.010 
Reference 
values (ng g-1) 
<0.093 0.305 ± 0.051 5.00 ± 0.44 0.878 ± 0.077 0.39 ± 0.12 0.172 ± 0.036 <0.025 - 0.203 <0.131 <0.448 NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table A5. PFSA concentrations (mean ± 95% confidence intervals) measured in n = 3 replicates of NIST SRM 1957 compared to reference 
values. ND = non-detect. NA = not available.  
 PFBS br-PFHxS l-PFHxS Total PFHxS br-PFOS l-PFOS Total PFOS 
Mean (n g-1) <0.01 0.11 ±  0.071 4.02 ± 2.28 4.13 ± 2.35 8.12 ± 2.06 12.6 ± 3.64 20.7 ± 5.41 
Reference values (ng g-1)  <0.25 NA NA 4.00 ± 0.83 NA NA 21.1 ± 1.3 
 Table A6. Method detection limits (ng g-1) for PFASs analyzed in each of the three batches. 
Target Analytesa, c Batch 1 Batch 2 Batch 3 
PFBS 0.01 0.01 0.09 
PFHxS 0.01 0.01 0.02 
PFOS 0.01 0.01 0.04 
PFHxA 0.3 0.1 0.08 
PFHpA 0.04 0.1 0.14 
PFOA 0.2 0.25 0.03 
PFNA 0.05 0.1 0.03 
PFDA 0.05 0.07 0.07 
PFUnDA 0.05 0.05 0.02 
PFDoDA 0.05 0.05 0.03 
PFTrDA 0.05 0.05 0.02 
PFTeDA 0.05 0.05 0.07 
PFPeDA 0.05 0.03 n.a. 
n.a. not available. 
 
  
  
Table A7. Concentrations of PFAAs in serum from 2-4-month-old children sampled 1996-
1999, living in different drinking water districts in Uppsala Countya 
  Uppsala districts receiving different percentages of  
PFAA-contaminated drinking water 
PFAA (ng g-1) Outside of 
Uppsala 
0% <10% 10-90% >90% 
PFHxA 0.093 (0.006) 0.094 (0.0060) 0.14 (0.043) 0.087 (0.013) 0.080 (0.010) 
PFOA 7.4 (0.58) 6.4 (0.45) 9.4 (3.7) 6.4 (1.1) 7.3 (1.1) 
PFBS 0.0090 (0.0010) 0.010 (0.0010) 0.0070 (0.0050) 0.013 (0.0040) 0.029 (0.0070)a 
PFHxS 1.7 (0.15) 2.1 (0.16) 3.0 (1.3) 2.6 (0.52) 5.5 (0.91)a 
%br PFHxS 6 (0.40) 6.0 (0.40) 6.0 (2.0) 9.0 (0.90)a 10 (0.8)a 
PFOS 13 (0.87) 12 (0.74) 17 (5.9) 9.9 (1.6) 14 (1.8) 
%br PFOS 37 (0.90) 36 (0.80) 36 (4) 40 (2) 34 (2) 
aLeast square means and standard error. In the GLM analyses the covariates “gestational length”, “infant weight gain after 
birth”, and “duration of nursing” were included. a = significantly different (p<0.05) from drinking water district “Outside of 
Uppsala”, as determined in multiple regression analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
 Table A8. The influence of maternal weight gain during pregnancy and birth weight on 
percent change in serum PFAA concentrations per unit change of gestational age in 
exclusively breastfed infants.a 
PFAA +maternal weight gain +birth weight 
 β (% change) (p) β (% change) (p) 
PFOA 0.66 (0.30) (0.030) 0.46 (0.33) (0.165) 
PFNA 1.3 (0.42) (0.003) 1.2 (0.47) (0.015) 
Linear PFOS 0.77 (0.35) (0.029) 0.87 (0.38) (0.027) 
PFOS 0.86 (0.37) (0.021) 0.91 (0.41) (0.030) 
aAdjusted mean (standard error). Covariates ‘maternal PFAA’, ‘breastfeeding’ and ‘infant weight gain’ was included in the 
multiple regression model. Outliers with standardized residual ≥3 excluded in the regression analyses. 
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